Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy
| Autor: | Michael Eisenhut, Bernhard Haller, Matthias Eiber, Markus Schwaiger, Hans-Jürgen Wester, Michael Souvatzoglou, Uwe Haberhorn, Frank Philipp Graner, Tobias Maurer, Hubert Kübler, Alexander Ruffani, Jürgen E. Gschwend, Ambros J. Beer |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Biochemical recurrence
PET-CT medicine.diagnostic_test business.industry Prostatectomy medicine.medical_treatment Retrospective cohort study urologic and male genital diseases medicine.disease Prostate cancer Prostate-specific antigen Positron emission tomography medicine Carcinoma Radiology Nuclear Medicine and imaging Nuclear medicine business |
| Zdroj: | Journal of Nuclear Medicine. 56:668-674 |
| ISSN: | 2159-662X 0161-5505 |
| DOI: | 10.2967/jnumed.115.154153 |
| Popis: | The expression of prostate-specific membrane antigen (PSMA) is increased in prostate cancer. Recently, 68Ga-PSMA (Glu-NH-CO-NH-Lys-(Ahx)-[68Ga(HBED-CC)]) was developed as a PSMA ligand. The aim of this study was to investigate the detection rate of 68Ga-PSMA PET/CT in patients with biochemical recurrence after radical prostatectomy. Methods: Two hundred forty-eight of 393 patients were evaluable for a retrospective analysis. Median prostate-specific antigen (PSA) level was 1.99 ng/mL (range, 0.2–59.4 ng/mL). All patients underwent contrast-enhanced PET/CT after injection of 155 ± 27 MBq of 68Ga-PSMA ligand. The detection rates were correlated with PSA level and PSA kinetics. The influence of antihormonal treatment, primary Gleason score, and contribution of PET and morphologic imaging to the final diagnosis were assessed. Results: Two hundred twenty-two (89.5%) patients showed pathologic findings in 68Ga-PSMA ligand PET/CT. The detection rates were 96.8%, 93.0%, 72.7%, and 57.9% for PSA levels of ≥2, 1 to 6, 4–6, and |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|